Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Operations (2016 - 2025)

Iovance Biotherapeutics has reported Cash from Operations over the past 12 years, most recently at 52608000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 52608000.0 for Q4 2025, up 28.23% from a year ago — trailing twelve months through Dec 2025 was 302408000.0 (up 14.33% YoY), and the annual figure for FY2025 was 302408000.0, up 14.33%.
  • Cash from Operations for Q4 2025 was 52608000.0 at Iovance Biotherapeutics, up from 78659000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for IOVA hit a ceiling of 52608000.0 in Q4 2025 and a floor of 122279000.0 in Q1 2024.
  • Median Cash from Operations over the past 3 years was 84026500.0 (2023), compared with a mean of 84767083.33.
  • Peak annual rise in Cash from Operations hit 31.48% in 2025, while the deepest fall reached 33.38% in 2025.
  • Iovance Biotherapeutics' Cash from Operations stood at 83970000.0 in 2023, then increased by 12.71% to 73296000.0 in 2024, then rose by 28.23% to 52608000.0 in 2025.
  • The last three reported values for Cash from Operations were 52608000.0 (Q4 2025), 78659000.0 (Q3 2025), and 67447000.0 (Q2 2025) per Business Quant data.